EC Pharmacology and Toxicology

The search for new biologically active compounds is an urgent task of modern pharmacology and medicine. N₁-methylnicotinamide is a first metabolite of vitamin PP. Its biological properties were poorly understood last decades. Some studies have shown protective effect of N₁-methylnicotinamide on ischemia-reperfusion injury in the liver and skin pathology. The purpose of this work is to analyze literary and own data on the results of the use of N₁-methylnicotinamide for various pathologies.

Keywords: N₁-Methylnicotinamide; Oxidative Stress; Liver; Ischemia-Reperfusion

1. Mateuszuk L, et al. “Activation of nicotinamide N-methyltrasferase and increased formation of 1-methylnicotinamide (MNA) in atherosclerosis”. Pharmacological Reports1 (2009): 76-85.
2. Gebicki J., et al. “1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin origin”. Polish Journal of Pharmacology1 (2003): 109-112.
3. Adamiec M., et al. “Search for drugs of the combined anti-inflammatory and anti-bacterial properties: 1-methyl-N'-(hydroxymethyl)nicotinamide”. Pharmacological Reports2 (2006): 246-249.
4. Kuznetsov DA., et al. “Effect of magnesium pool isotopy on the recovery of mitochondrial ATP synthesis inhibited by 1-methylnicotinamide”. Biomedical Chemistry2 (2006): 146-152.
5. Zhou SS., et al. “Nicotinamide overload may play a role in the development of type 2 diabetes”. World Journal of Gastroenterology45 (2009): 5674-5684.
6. Watała C., et al. “Anti-diabetic effects of 1-methylnicotinamide (MNA) in streptozocin-induced diabetes in rats”. Pharmacological Reports1 (2009): 86-98.
7. Mogielnicki A., et al. “N-methylnicotinamide failed to induce endothelial prostacyclin release in perfused rat hindquarters”. Pharmacological Reports6 (2008): 1025-1029.
8. Chlopicki S., et al. “1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway”. British Journal of Pharmacology2 (2007): 230-239.
9. Jakubowski A., et al. “1-Methylnicotinamide protects against liver injury induced by concanavalin A via a prostacyclin-dependent mechanism: A possible involvement of IL-4 and TNF-α”. International Immunopharmacology 31 (2016): 98-104.
10. Brzozowski T., et al. “Therapeutic potential of 1-methylnicotinamide against acute gastric lesions induced by stress: role of endogenous prostacyclin and sensory nerves”. Journal of Pharmacology and Experimental Therapeutics1 (2008): 105-116.
11. Dragun P., et al. “Matrix metaloproteinases activity during the evolution of hypoxic-ischemic brain damage in the immature rat. The effect of 1-methylnicotinamide (MNA)”. Journal Physiology and Pharmacology3 (2008): 441-455.
12. Shulga EV and Zinchuk VV. “The effect of 1-methylnicotinamide on the oxygen transport function of the blood and free radical processes with the introduction of lipopolysaccharide”. News of Biomedical Science 3 (2009): 17-22.
13. Riederer M., et al. “Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine”. Atherosclerosis2 (2009): 412-417.
14. Khodosovskiĭ MN., et al. “Effect of 1-methylnicotinamide on prooxidant-antioxidant balance parameters in rats during hepatic ischemia-reperfusion”. Eksp Klin Farmakol4 (2010): 11-13.
15. Khodosovskiĭ MN and Zinchuk VV. “The blood oxygen transport parameters in rats during hepatic ischemia-reperfusion under 1-methylnicotinamide administration”. Journal of Grodno State Medical University2 (2009): 52-54.
16. Khodosovsky MN. “Participation of gasotransmitters in the correction of hepatic reperfusion injury”. Grodno: GrSMU (2017): 212.
17. Kolodziejczyk AM., et al. “Nanomechanical sensing of the endothelial cell response to anti-inflammatory action of 1-methylnicotinamide chloride”. International Journal of Nanomedicine 8 (2013): 2757-2767.
18. Renga B., et al. “Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1”. PLoS One11 (2015): e0141082.